NxStage Medical announces CE Mark approval for noctural home hemodialysis NxStage Medical announced CE Mark approval for nocturnal home hemodialysis with the NxStage System One. NxStage expects to begin marketing the System One for nocturnal dialysis in countries that recognize the CE Mark approval process in the second half of 2013.
NxStage Medical sees FY16 revenue $355M-$360M, consensus $371.03M Sees FY16 net loss in range of $7M-$12M. The company commented, "Our guidance for the full fiscal year 2016 includes continued strong performance from our System One segment, with expectations for annual growth within Home and Critical Care of 15 percent and 9 percent, respectively, and a modest increase in our Services segment. We've also guided to a much lower revenue level for our low margin In-Center segment."